Cationic Lipid Compositions for mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering biologically active agents, such as RNAi agents, face challenges in reaching target cells due to cellular membrane restrictions, requiring high concentrations that can lead to toxic side effects, and existing cationic lipids are not optimized for systemic and local delivery, especially to tumors outside the liver.
Innovation Solution
A lipid composition comprising ((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(octane-8,1-diyl) or (9Z,9'Z,12Z,12'Z)-((5-((dimethylamino)methyl)-1,3-phenylene)bis(oxy))bis(butane-4,1-diyl) bis(octadeca-9,12-dienoate) combined with mRNA, which enhances cellular uptake and stability, with potential adjustments in cationic lipid formulations to target specific organs and tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of biologically active agents are used to overcome cellular membrane restrictions, then delivery effectiveness is improved, but toxic side effects increase
Solution Approach 1:
The patent employs cationic lipid carriers as intermediary substances that mediate the delivery of biologically active agents across cellular membranes. These lipid carriers form complexes with the agents, enabling them to traverse membrane barriers without requiring high concentrations, thus maintaining delivery effectiveness while reducing toxic side effects.
Solution Approach 2:
The invention modifies the physical and chemical parameters of the delivery system by using cationic lipids with specific properties (positive charge, amphiphilic nature) that enable effective cellular uptake. This parameter change allows the biologically active agents to be delivered at lower concentrations, resolving the contradiction between delivery effectiveness and toxicity.
2Ease of operation
If cationic lipids are used to facilitate cellular uptake of biologically active agents, then membrane transport is improved, but optimization for systemic and local delivery to specific organs and tumors remains insufficient
Solution Approach 1:
The patent applies the local quality principle by designing cationic lipid formulations with specific compositional variations that enable targeted delivery to different organs and tumor types. By adjusting the local properties of the lipid carriers (such as chain length, charge density, and auxiliary lipid composition), the system achieves both effective membrane transport and organ-specific targeting.
Solution Approach 2:
The invention uses composite lipid materials combining cationic lipids with auxiliary lipids and other components to create formulations that simultaneously provide membrane transport capability and targeting functionality. These composite materials integrate multiple functions within a single delivery system, addressing both membrane uptake and specific organ/tumor targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipid composition improves the systemic and local delivery of biologically active agents, including mRNA, by facilitating quantitative encapsulation and membrane transport, potentially reducing toxic effects and enhancing therapeutic efficacy.
Implementation Method 1
The encapsulation of anionic compounds using cationic lipids is essentially quantitative due to electrostatic interaction
Implementation Method 2
it is believed that the cationic lipids interact with the negatively charged cell membranes initiating cellular membrane transport
Data Source
AI summary
This invention provides for a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein R1-R4, L and X are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic lipids useful in the delivery of biologically active agents to cells and tissues.